Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
2024-06-04 · Total Series A after extension · $71 million total Series A ↗
The announcement states the full-round total after extension, not incremental funding raised that day.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
2026-07-10: Vilya-1 preprint explores macrocycle conformations and permeability modeling
2026-07-28: Vilya-2 preprint extends all-atom modeling to macrocycle–target interfaces
Program / service
Target / indication
Representative stage
Evidence & scope
α4β7 program
α4β7 · Inflammatory bowel disease
未披露
Quantitative human results not confirmed in this review
Oncology A/B
Not disclosed · Oncology
未披露
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Vilya-2 extends the company’s all-atom representation from individual molecules to interactions with protein targets using a diffusion-transformer model. The preprint focuses on noncanonical residues, macrocyclization, and complex topologies. Company examples include modeling icotrokinra and enlicitide complexes. Structural predictions support discovery hypotheses rather than proving oral exposure or clinical activity for newly designed candidates.
Vilya’s technical preprint describes an all-atom model for conformational sampling and developability prediction across macrocycles with diverse chemistries and noncanonical residues. The framework supports permeability modeling and molecular design within the company’s oral-macrocycle strategy. Computational benchmark performance does not demonstrate human oral bioavailability, efficacy, or safety; the report is a preprint rather than peer-reviewed clinical evidence.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
